1	Distinct impact of IgG subclass and Fc-FcyR interaction on autoantibody
2	pathogenicity in different IgG4-mediated diseases
3	Yanxia Bi ^{1,2} , Jian Su ^{3,4} , Shengru Zhou ⁵ , Yingjie Zhao ^{1,2} , Yan Zhang ^{1,2} , Huihui Zhang ^{1,2} ,
4	Mingdong Liu ^{1,2} , Aiwu Zhou ² , Meng Pan ⁵ , Yiming Zhao ^{3,4*} , Fubin Li ^{1,2,6*}
5	¹ Shanghai Institute of Immunology, Faculty of Basic Medicine, Shanghai Jiao Tong University
6	School of Medicine, Shanghai 200025, China
7	² Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,
8	Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
9	³ Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou
10	215006, China
11	⁴ Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China
12	⁵ Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of
13	Medicine, Shanghai 200025, China
14	⁶ Leading contact: Fubin Li (fubin.li@sjtu.edu.cn)
15	*Address correspondence to Fubin Li (0086-18918925314; fubin.li@sjtu.edu.cn) or Yiming
16	Zhao (0086-13862045330; zhaoyimingbox@163.com)
17	

18 Abstract

19	IgG4 is the least potent human IgG subclass for the FcγR-mediated antibody effector function
20	and is considered anti-inflammatory in the context of prolonged inflammation and allergic
21	responses. Paradoxically, IgG4 is also the dominant IgG subclass of pathogenic autoantibodies in
22	IgG4-mediated diseases. Here we show that the IgG subclass and Fc-FcyR interaction have a
23	distinct impact on the pathogenic function of autoantibodies in different IgG4-mediated diseases.
24	While IgG4 and its weak $Fc-Fc\gamma R$ interaction have an ameliorative role in the pathogenicity of
25	anti-ADAMTS13 autoantibodies isolated from thrombotic thrombocytopenic purpura (TTP)
26	patients, they have an unexpected exacerbating effect on anti-Dsg1 autoantibody pathogenicity in
27	pemphigus foliaceus (PF) models. Strikingly, a non-pathogenic anti-Dsg1 antibody variant
28	optimized for FcyR-mediated effector function can attenuate the skin lesions induced by
29	pathogenic anti-Dsg1 antibodies by promoting the clearance of dead keratinocytes. These studies
30	suggest that IgG effector function contributes to the clearance of autoantibody-Ag complexes,
31	which is harmful in TTP, but beneficial in PF and may provide new therapeutic opportunity.

32 Introduction

IgG4, the least expressed IgG subclass in humans, is a highly relevant IgG subclass in a range of 33 IgG4-mediated autoimmune diseases and IgG4-related diseases, both of which are still 34 expanding (Huijbers, Plomp, van der Maarel, & Verschuuren, 2018; Koneczny, 2018; Umehara 35 et al., 2017). It is generally accepted that IgG4 has the poorest effector function among all human 36 natural IgG subclasses and is anti-inflammatory (Lighaam & Rispens, 2016). This is due to the 37 38 unique features of IgG4, including its low affinity to FcyRs and lack of capacity to activate complements, as well as its reduced ability to form immune complex due to a unique process 39 referred to as Fab-arm exchange (Lighaam & Rispens, 2016; Vidarsson, Dekkers, & Rispens, 40 41 2014). The Fab-arm exchange between different IgG4 antibodies results in the formation of heterodimeric IgG4 molecules (*i.e.*, bi-specific IgG4 antibodies) that only allow monovalent 42 binding (Koneczny, 2018; Lighaam & Rispens, 2016). Given these features, it has been 43 speculated that the choice of IgG4 subclass in autoantibodies in various relevant autoimmune 44 diseases may be protective by reducing or preventing the pathogenic function of more harmful 45 antibody classes or subclasses (Rihet, Demeure, Dessein, & Bourgois, 1992). IgG4 46 autoantibodies targeting the acetylcholine receptor (AChR) have been reported to protect 47 48 monkeys from myasthenia gravis induced by matched IgG1 autoantibodies (van der Neut 49 Kolfschoten et al., 2007). Allergen-specific IgG antibodies derived from hyperimmune 50 beekeepers, mostly IgG4, have been reported to be protective in allergy patients (Devey, Lee, 51 Richards, & Kemeny, 1989) and mouse models (Schumacher, Egen, & Tanner, 1996). 52 Phospholipase A₂ (PLA) specific autoantibodies in patients with bee venom allergy switched 53 from IgE to IgG4 after effective antigen-specific immunotherapy (Akdis & Akdis, 2011; Devey et al., 1989). 54

IgG4-mediated autoimmune diseases represent a unique category of more than ten autoimmune 55 conditions featured by the accumulation of pathogenic antigen-specific IgG4 autoantibodies. The 56 pathogenic function of IgG4 autoantibodies has been either well established or highly suspected 57 in the majority of these diseases (Huijbers et al., 2018; Koneczny, 2018). Among them, 58 thrombotic thrombocytopenic purpura (TTP) and pemphigus foliaceus (PF) are two well-studied 59 60 examples, in which both disease-triggering autoantibodies and their antigenic targets have been identified. In PF, autoantibodies bind to Dsg1 (desmoglein 1), a desmoglein protein highly 61 62 expressed in the superficial layers of the epidermis and essential for adhesion between 63 neighboring keratinocytes, and result in the loss of cell-cell adhesion and the blistering of skin (Anhalt, Labib, Voorhees, Beals, & Diaz, 1982; Korman, Eyre, Klaus-Kovtun, & Stanley, 1989; 64 Rock et al., 1989). ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 65 1 motif, member 13), the critical enzyme maintaining the homeostasis of von Willebrand Factor 66 (vWF) in the plasma, is targeted by autoantibodies in acquired TTP (Zheng, 2015). In both PF 67 68 and TTP patients, IgG4 is a major autoantibody subclass, and its levels correlate with disease activities (Ferrari et al., 2009; Rock et al., 1989; Sinkovits et al., 2018; Warren et al., 2003). 69 Importantly, polyclonal anti-Dsg1 and ADAMTS13 enriched from patient plasma, as well as 70 71 monoclonal anti-Dsg1 and -ADAMTS13 autoantibodies isolated from patients, are pathogenic in 72 both in vitro assay and animal models (Huijbers et al., 2018; Koneczny, 2018). These studies, 73 together with the study of other IgG4-mediated diseases and IgG4-related diseases (Shiokawa et 74 al., 2016), have established that IgG4 autoantibodies are pathogenic and highly relevant to the development of these diseases (Huijbers et al., 2018; Koneczny, 2018). 75 76 It is, however, not clear whether the IgG4 subclass in these IgG4 autoantibodies has any impact 77 on their pathogenicity. Most studies supported the notion that IgG4 is the most prevalent IgG

78	subclass in anti-ADAMTS13 autoantibodies and is associated with disease relapse (Ferrari et al.,
79	2009; Sinkovits et al., 2018). At the same time, IgG1 and IgG3 autoantibody levels appear to
80	have a stronger correlation with disease severity in acquired TTP patients during the acute phase
81	(Bettoni et al., 2012). In contrast, pathogenic anti-Dsg1 autoantibodies often have the IgG4
82	subclass, whereas non-pathogenic anti-Dsg1 autoantibodies often have the IgG1 subclass in
83	endemic PF patients (Aoki, Rivitti, Diaz, & Cooperative Group on Fogo Selvagem, 2015;
84	Warren et al., 2003). However, it is also reported that these pathogenic and non-pathogenic anti-
85	Dsg1 autoantibodies have different binding epitopes (Aoki et al., 2015; Li, Aoki, Hans-Filho,
86	Rivitti, & Diaz, 2003). Therefore, despite that IgG4 autoantibodies are pathogenic, and that some
87	autoantibodies isolated from IgG4-mediated diseases (anti-Dsg1, e.g.) are pathogenic in the form
88	of scFv and Fab fragments (Ishii, Lin, Siegel, & Stanley, 2008; Rock, Labib, & Diaz, 1990;
89	Yamagami et al., 2009), it does not rule out the possibility that the choice of IgG4 in these
90	autoantibodies is a protective mechanism against the otherwise more harmful antibody classes or
91	subclasses.
92	Furthermore, it appears that antibodies with different modes of action, including effector
93	antibodies, agonistic, and blocking antibodies, could be impacted by IgG subclasses and Fc-FcyR
94	interactions in different ways. Both humans and mice have activating and inhibitory $Fc\gamma Rs$ that
95	mediate or inhibit antibody effector functions, respectively. Either ablating activating $Fc\gamma Rs$
96	expression or ectopically overexpressing inhibitory FcyRIIB can protect autoimmune mice from
97	premature mortality (Clynes, Dumitru, & Ravetch, 1998; McGaha, Sorrentino, & Ravetch,
98	2005), as well as arthritic antibody-induced joint inflammation in murine models (Ji et al., 2002).
99	Studies of blocking and agonistic antibodies, which exert their function in entirely different

- 100 ways, also revealed a critical impact of both murine and human IgG subclasses and Fc-FcγR
- 101 interactions on the activities of these antibodies (Dahan et al., 2015; Liu et al., 2019).
- 102 In this study, we reasoned that studying whether and how IgG subclasses and Fc-FcγR
- interactions impact on autoantibody pathogenicity in the context of IgG4-mediated diseases can
- help us to understand the modes of action of IgG4 autoantibodies and disease pathogenesis. Anti-
- 105 Dsg1 and ADAMTS13 autoantibodies isolated from IgG4-mediated diseases were investigated
- in physiologically relevant models where intact human IgG autoantibodies can interact with both
- 107 their antigenic targets and Fc-receptor expressing cells.

108

109 Results

110 *IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies*

111 To directly test whether the IgG subclass of anti-ADAMTS13 autoantibodies has any impact on

- their pathogenicity, a pathogenic monoclonal anti-ADAMTS13 antibody (clone TTP1-420)
- previously isolated from TTP patient and confirmed in mice (Ostertag, Bdeir, et al., 2016;
- 114 Ostertag, Kacir, et al., 2016) was expressed as either human IgG4 or IgG1 antibodies. These
- antibodies were confirmed to have similar binding kinetics to human ADAMTS13 (Fig. S1A).
- 116 Anti-ADAMTS13 autoantibodies have been previously shown to mediate their pathogenic effect
- by inhibiting the enzymatic activity of ADAMTS13, which leads to an increased ultra-large form

of von Willebrand factor (vWF) and platelet binding and activation (Zheng, 2015). To evaluate

- the pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1) autoantibodies, their impact on
- 120 ADAMTS13 enzymatic activity was analyzed firstly in WT mice (Fig. 1A). As shown in Fig.
- 121 1B, both TTP1-420(IgG4) and TTP1-420(IgG1)-treated WT mice displayed a significant
- reduction in ADAMTS13 activity soon after the treatment. However, the recovery of
- ADAMTS13 activity is significantly faster in TTP1-420(IgG4)-treated mice than in TTP1-
- 420(IgG1)-treated mice, with almost complete recovery by day 8 in the former group and nearly
- no recovery in the latter group (Fig. 1, B and C).
- 126 To further evaluate the pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1) autoantibodies in
- 127 the more physiologically relevant model with human Fcy-receptor background, FcyR-humanized
- 128 mice (hFCGR^{Tg}) that recapitulate the expression profile of human FcγRs (Smith, DiLillo,
- Bournazos, Li, & Ravetch, 2012) were used (Fig. 1A). Consistently, TTP1-420(IgG4)
- autoantibodies also displayed weaker pathogenicity as compared to TTP1-420(IgG1)
- 131 autoantibodies in FcγR-humanized mice (Fig. 1, D and E). These results suggest that while both

- 132 IgG4 and IgG1 anti-ADAMTS13 autoantibodies can inhibit ADAMTS13 activity, IgG4
- autoantibodies are less pathogenic as compared to IgG1 autoantibodies. Therefore, it appears that
- switching to the IgG4 subclass in anti-ADAMTS13 autoantibodies represents a protective
- 135 mechanism.



Fig. 1. IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies. (A) Schematic 137 diagram of the experimental design. In brief, wide-type C57BL/6 or hFCGR^{Tg} mice were treated 138 with 10 µg of control human IgG (Ctrl hIgG, $n \ge 3$), or anti-ADAMTS13 TTP1-420(IgG1) or 139 TTP1-420(IgG4) ($n \ge 4$) on day 0 through tail vein injection, blood was collected on day -1, day 140 1, day 5 and day 8 and analyzed for ADAMTS13 activity. (B-E) Plots showing ADAMTS13 141 activity in the plasma of WT (B, C) or hFCGR^{Tg} (D, E) mice treated with the indicated 142 antibodies at the indicated time points and analyzed by the FRETS-VWF73 assay, represented as 143 relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D), and the RFU 144

145	change within 1 hour on day -1 and day 8 (C, E). Mean \pm SEM values are plotted. Two-way
146	ANOVA with Tukey's (B, D) or Sidak's (C, E) multiple comparisons tests. * $p < 0.05$, ** $p <$
147	0.01, *** $p < 0.001$, **** $p < 0.0001$. A representative of two independent experiments is
148	shown.

149

Activating FcγR-mediated IgG effector function enhances the pathogenicity of anti-ADAMTS13
autoantibodies

152 Human IgG4 and IgG1 are very different in mediating FcγR-dependent effector function, with

153 IgG4 being much less potent due to its weaker binding affinity to activating $Fc\gamma Rs$ (5, 33),

including both mouse and human activating FcγRs (References (29, 33, 34) and Fig. S1B). To

understand the basis of the differential pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1)

156 autoantibodies, we investigated whether Fc-FcyR interaction impacts on anti-ADAMTS13

autoantibody pathogenicity using Fc γ R-deficient mice (Fc γ R α ^{null}) (Fig. 2A). As shown in Fig.

158 2B, while TTP1-420(IgG1)-treated WT and $Fc\gamma R\alpha^{null}$ mice displayed comparable levels of

reduction in ADAMTS13 activity at the early time points (day 1 and day 5) (Fig. 2B), the

160 recovery of ADAMTS13 activity is significantly faster in $Fc\gamma R\alpha^{null}$ mice (Fig. 2, B and C).

161 These results suggest that while FcyR-mediated function is not essential for the pathogenicity of

162 anti-ADAMTS13 autoantibodies, it has an enhancing effect. Further investigation in Fc receptor

163 common γ -chain deficient mice (*Fcer1g*^{-/-}), which lack functional activating Fc γ Rs, showed that

164 *Fcer1g^{-/-}* mice have accelerated recovery of ADAMTS13 enzyme activity (Fig. 2, A, D and E),

suggesting that activating Fcy receptors are responsible for the enhancing effect of FcyRs to the

166 pathogenicity of anti-ADAMTS13 autoantibodies.



Fig. 2. The protective effect of the IgG4 subclass in anti-ADAMTS13 autoantibodies is due to reduced Fc γ R-mediated antibody effector function. (A) Schematic diagram of the experimental design. In brief, WT, Fc γ R α^{null} , or *Fcer1g*^{-/-} mice were treated and analyzed as in Fig. 1A. (B-E) Plots showing ADAMTS13 activity in the plasma of WT and Fc γ R α^{null} mice (B, C), WT and *Fcer1g*^{-/-} mice (D, E), or WT mice (F, G) treated with the indicated antibodies and analyzed at indicated time points as in Fig. 1, B and C, represented as RFU changing rates over time

174	(RFU/min) (B, D, F), and the RFU change within 1 hour on the indicated days (C, E, G). Mean \pm
175	SEM values are plotted. Two-way ANOVA with Sidak's (B-E and G) or Tukey's (F) multiple
176	comparisons tests. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. A representative of
177	two independent experiments is shown.
178	
179	To rule out the possibility that non-Fc γ R factors are responsible for the reduced pathogenic
180	function of anti-ADAMTS13 autoantibodies in $Fc\gamma R\alpha^{null}$ and $Fcer1g^{-/-}$ mice, WT mice were
181	treated with two variants of TTP1-420(IgG1) autoantibodies with different FcyR-binding
182	property (Fig. 2A, Table S1): 1) the N297A variant with reduced FcyR-binding and effector
183	function (Fig. S1B and references (Sazinsky et al., 2008)); 2) the GASDALIE variant with
184	enhanced FcyR-binding and effector function (Fig. S1B and References (Bournazos, DiLillo,
185	Goff, Glass, & Ravetch, 2019)). As shown in Fig. 2F, while both TTP1-420(N297A) and TTP1-
186	420(GASDALIE) autoantibodies induced a significant reduction in ADAMTS13 enzyme activity
187	(Fig. 2F), TTP1-420(N297A)-treated mice recovered much faster (Fig. 2, F and G). These results
188	suggest that while the activating FcyR-mediated effector function is not absolutely required for
189	the pathogenic function of anti-ADAMTS13 autoantibodies, it does have a critical enhancing
190	effect, likely by depleting ADAMTS13-autoantibodies immune complex.
191	IgG4 autoantibodies deplete relatively less ADAMTS13 in acquired TTP patients
192	To investigate whether IgG4 autoantibodies have a less depleting effect on ADAMTS13, plasma
193	samples of a cohort of 44 acquired TTP patients were analyzed (Table S2). The majority of these
194	samples were confirmed to contain anti-ADAMTS13 autoantibodies, with 43 out of 44 TTP
195	samples have anti-ADAMTS13 autoantibody signal levels that are two-fold higher than healthy
196	control (HC) average levels, which were considered as the background (Fig. 3, A and F). All





204	Fig. 3. ADAMTS13-specific IgG1 levels in the plasma of acquired TTP patients inversely
205	correlate to the ADAMTS13 Ag levels and activity. (A-C) Plots showing ADAMTS13-specific
206	IgG (A), ADAMTS13 activity (B), and ADAMTS13 antigen (C) levels in the plasma of HC (n =
207	23) and acquired TTP patients during the acute phase ($n = 44$). (D) Plot showing correlation
208	analysis of ADAMTS13 activity with ADAMTS13 Ag concentration in TTP patients. (E)
209	ADAMTS13-specific IgG1 (left panel) and IgG4 (right panel) levels in the plasma of TTP
210	patients and HC. (F) Plot showing correlation analysis of ADAMTS13-specific IgG1 with IgG4
211	levels in TTP patients, with the threshold for IgG1 and IgG4 autoantibodies (two times of HC
212	average values) annotated. (G-J) Plots showing correlation analysis between the anti-
213	ADAMTS13 IgG1 (G, H) and IgG4 (I, J) levels with ADAMTS13 activity (G, I) and
214	ADAMTS13 Ag (H, J) levels in TTP patients, respectively. (K) Plots showing IgG1 and IgG4
215	anti-ADAMTS13 levels in TTP plasma samples normalized to HC, with IgG1 dominant TTP and
216	IgG4 dominant TTP samples annotated. (L, M) Plotting showing ADAMTS13 activity (L) and
217	antigen (M) levels in TTP plasma samples as annotated in (K). Each symbol is derived from an
218	individual plasma sample. Mean \pm SEM values are plotted. Unpaired nonparametric Mann-
219	Whitney test (A, B, C, E, L, M) or linear regression analysis (D, F-J). *** $p < 0.001$, ****
220	0.0001, ns, non-significant.

221

Interestingly, while IgG1 autoantibodies have a significant inverse correlation with ADAMTS13
antigen and activity levels, IgG4 autoantibodies do not (Fig. 3, G to J), suggesting that IgG4
autoantibodies have relatively less impact on ADAMTS13 antigen and activity levels.
Given the inverse correlation between IgG1 and IgG4 autoantibodies in these TTP samples, they

were divided into two groups: IgG1 and IgG4 dominant TTP samples, respectively (Fig. 3K).

Notably, while these two groups have similar ADAMTS13 activity levels (Fig. 3L), the IgG4 227 dominant group has significantly higher ADAMTS13 antigen levels (Fig. 3M). These results 228 229 suggest that IgG4 anti-ADAMTS13 autoantibodies confer relatively less ADAMTS13 depletion. *IgG4 and IgG1 anti-Dsg1 autoantibodies have shared binding epitopes and different abundance* 230 in PF patients 231 Previously, it has been described that the IgG1 anti-Dsg1 autoantibodies are observed in both 232 233 healthy subjects and endemic PF patients, and the accumulation of IgG4 anti-Dsg1 234 autoantibodies is a key step in the development of the disease (Warren et al., 2003). At the same 235 time, the binding epitope of anti-Dsg1 autoantibodies is critical for the pathogenicity of anti-Dsg1 autoantibodies (Li et al., 2003), raising the possibility that IgG4 and IgG1 anti-Dsg1 236 237 autoantibodies bind to different Dsg1 epitopes (Aoki et al., 2015). To investigate whether the 238 binding epitope represents a major difference between IgG1 and IgG4 anti-Dsg1 autoantibodies, 239 serum samples of a cohort of 53 PF patients admitted to Rui Jin Hospital, Shanghai, China, were 240 analyzed for the total levels and subclasses of IgG anti-Dsg1 autoantibodies (Table S3). 241 Consistent with previous studies (Warren et al., 2003), PF patients have both IgG4 and IgG1 242 anti-Dsg1 autoantibodies (Fig. 4A). However, IgG4 autoantibodies are much more abundant than IgG1 autoantibodies (Fig. 4A, and Fig. S2A). Based on the clinical symptoms and medication, 243 these PF patients were assigned to the "stable" and "active" groups. Both groups have more IgG4 244 autoantibodies than IgG1 autoantibodies (Fig. S2A). The "active" PF samples have higher 245 246 autoantibody levels as compared to the "stable" PF samples, regardless of what IgG subclasses were considered (Fig. S2A). 247 The binding epitopes of IgG4 and IgG1 anti-Dsg1 autoantibodies were analyzed based on their 248

binding to a series of Dsg1/Dsg2 chimeric proteins containing different Dsg1 extracellular

domains (Fig. S2B). Interestingly, all the tested samples with significant IgG1 antibodies showed
that their IgG1 and IgG4 anti-Dsg1 autoantibodies have the same chimeric antigen-binding
profiles (Fig. 4B). These results suggest that IgG1 and IgG4 anti-Dsg1 autoantibodies have
different abundance but shared binding epitopes, at least in the patient samples analyzed in our
study, and that the IgG subclass of these anti-Dsg1 autoantibodies could be a key variable in PF
pathogenesis.

256 IgG4 is not less, if not more, pathogenic than IgG1 in anti-Dsg1 autoantibodies

257 To investigate the impact of IgG4 subclass on the pathogenicity of anti-Dsg1 autoantibodies, we

studied anti-Dsg1 autoantibodies previously isolated from PF patients and proven to be

259 pathogenic in both neonatal mouse and human tissue-culture models (Ishii et al., 2008;

260 Yamagami et al., 2009). Two anti-Dsg1 antibody clones (PF1-8-15 and PF24-9) were produced

as IgG1 and IgG4 antibodies and confirmed to bind to Dsg1 with similar kinetics (Fig. S3A).

262 When tested in neonatal mice, both human IgG4 and IgG1 anti-Dsg1 antibodies induced

epidermal acantholysis (Fig. S3B).

264 Since pemphigus is a chronic disease that often affects adults and older adults in the context of ongoing immune responses (Schmidt, Kasperkiewicz, & Joly, 2019), and the neonatal mouse 265 model is limited by the short time (usually for a few hours) allowed for investigation and its 266 267 underdeveloped immune system, we developed a PF model based on adult mice. As shown in Fig. S4A, adult hFCGR^{Tg} mice treated with PF24-9(IgG1) autoantibodies could reproduce the 268 clinical, histological and immunological features of PF patients, including erosions that heal with 269 270 crusting and scaling, intercellular deposition of human IgG in the epidermis at prelesion and lesion sites, and histopathological changes including ear and skin epidermal blistering formation. 271 In addition, we observed the thickened epidermis and leukocyte infiltration at the lesion sites 272

273	during the disease onset (Fig. S4A), which generally last for a few days depending on the amount
274	of autoantibody administered. These observations are consistent with previous analysis of skin
275	samples of pemphigus patients (Furtado, 1959; Rados, 2011) and the recent description of
276	lymphocyte infiltration at the lesion sites in patients (Yuan et al., 2017; Zhou et al., 2019).
277	Therefore, the adoptive transfer of anti-Dsg1 antibodies is sufficient to initiate pemphigus in
278	adult mice, in which the pathogenicity of anti-Dsg1 autoantibodies can be studied in the process
279	of disease onset and resolution and in the context of an intact immune system.
280	To investigate whether IgG subclass impacts on the pathogenicity of anti-Dsg1 autoantibodies,
281	the pathogenicity of high dosage of PF24-9(IgG4) and PF24-9(IgG1) autoantibodies was
282	evaluated in hFCGR ^{Tg} mice (Fig. S4B). When skin and ear tissues were analyzed, epidermal
283	blistering and leukocyte infiltration were observed in both PF24-9(IgG4) and PF24-9(IgG1)
284	autoantibody-treated mice (Fig. S4C). Interestingly, when the anti-Dsg1 autoantibody dosage is
285	reduced, it appears that PF24-9(IgG4) is not less, but tends to be more pathogenic than PF24-
286	9(IgG1) antibodies based on the histopathological symptoms (Fig. 4C), in contrast with our
287	analysis of anti-ADAMTS13 autoantibodies.
288	Anti-Dsg1 autoantibodies are more pathogenic in the absence of $Fc\gamma Rs$

289 To investigate whether Fc-Fc γ R interaction impacts on the pathogenicity of anti-Dsg1

antibodies, $Fc\gamma R\alpha^{null}$ mice were used. Strikingly, both PF24-9(IgG4) and PF24-9(IgG1)

autoantibodies induced more severe ear lesions in $Fc\gamma R\alpha^{null}$ mice than in hFCGR^{Tg} mice (Fig.

4C). Increased infiltration of myeloid effector cells (Fig. S5, A to C), especially inflammation-

- 293 relevant neutrophils (Fig. 4, D to F), was observed in the ears of $Fc\gamma R\alpha^{null}$ mice treated with
- either PF24-9(IgG4) or PF24-9(IgG1) autoantibodies. While these results suggest that anti-Dsg1

295 autoantibodies induced acute inflammation together with skin lesions, they also suggest an FcγR-





Fig. 4. IgG4 is not less, if not more, pathogenic than IgG1 in Dsg1 autoantibodies, and both
could be exacerbated by FcγRs deficiency. (A) Plots showing the Unit values of indicated Dsg1specific antibodies in the serum of PF patients (n = 53). (B) Plots showing the levels of IgG1 and

301	IgG4 antibodies	in two PF pat	tients that bind	to Dsg1, Dsg2,	or $Dsg1/Dsg2$	chimeric molecules
	L)				L) L)	

- 302 containing the indicated Dsg1 EC domains. (C) Representative photos showing the HE staining
- results of ears of hFCGR^{Tg} and Fc γ R α^{null} mice 3 days after being treated with 0.4 mg of Ctrl
- hIgG (n = 3), or PF24-9(IgG1) or PF24-9(IgG4) (n \ge 4) through tail vein injection. Scale bars:
- $200 \ \mu m. (D-F)$ Representative flow cytometry profiles (D) and plots showing the percentage (E)
- and cell number (F) of infiltrating neutrophils ($CD11b^+Gr1^{hi}$) among leukocytes ($CD45^+$) in the
- 307 ears of mice in (C). Each symbol is derived from an individual PF patient (A) or an individual
- mouse (E, F). Mean \pm SEM values are plotted (A, E, F). One-way ANOVA (A) and Two-way
- ANOVA (E, F) with Tukey's multiple comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.01
- 310 0.0001. A representative of two independent experiments is shown.
- 311

312 *Anti-Dsg1 autoantibodies with low affinity to FcyRs are more pathogenic*

- To further investigate whether Fc-FcγR interactions attenuate anti-Dsg1 autoantibody
- pathogenicity, the N297A and GASDALIE variants (with reduced FcγR binding and enhanced
- activating FcγR binding, respectively; references (Bournazos et al., 2019; Sazinsky et al., 2008))
- of IgG1 anti-Dsg1 autoantibodies were produced (Fig. S3A) and evaluated in the adult
- pemphigus model. Strikingly, the N297A variants of both pathogenic anti-Dsg1 clones (PF1-8-
- 15 and PF24-9) are much more potent than their matched GASDALIE variants in inducing ear
- lesions (Fig. 5A, and Fig. S6, A and B) and inflammation in hFCGR^{Tg} mice, as shown by
- 320 increased ear thickness and weight (Fig. 5, B and C, and Fig. S6, C and D), as well as increased
- 321 infiltration neutrophils (Fig. 5, D and E, Fig. S6, E to G). Histopathological analysis of skin
- lesions at an early time point (day 3) (Fig. S6A) and a later time point (day 6) (Fig. S6B)
- revealed that while both the PF1-8-15(N297A) and PF1-8-15(GASDALIE) variants could induce



324

Fig. 5. Anti-Dsg1 autoantibodies with reduced FcyR-binding are more pathogenic. (A) 325 Representative photos showing the HE staining results of ears of hFCGR^{Tg} mice 3 days after 326 327 being treated with 0.5 mg of Ctrl hIgG (n = 3), or PF24-9(N297A) or PF24-9(GASDALIE) autoantibodies (n = 5). Scale bars: 200 μ m. (B, C) Ear thickness (B) and weight (C) of hFCGR^{Tg} 328 mice in (A) when sacrificed at day 3. (D, E) Plots showing the percentage (D) and cell number 329 (E) of infiltrating neutrophils (CD11b⁺Gr1^{hi}) among leukocytes (CD45⁺) in the ears of mice in 330 (A). (F) Photos of nude mice 2 days after being treated with 0.4 mg of Ctrl hIgG or PF1-8-331 332 15(N297A) or PF1-8-15(GASDALIE) antibodies (n = 5). Each symbol is derived from an

individual mouse. Mean \pm SEM values are plotted. One-way ANOVA with Tukey's multiple comparisons test (C-E). * p < 0.05, ** p < 0.01.

335

skin lesions, the PF1-8-15(GASDALIE) variant-treated mice recovered faster. The pathogenic 336 function of N297A and GASDALIE anti-Dsg1 autoantibodies was also evaluated in nude mice, 337 where skin lesions can be better observed. As shown in Fig. 5F and Fig. S6I, PF1-8-15(N297A) 338 339 autoantibodies induced more severe skin lesions and slower recovery as compared to matched PF1-8-15(GASDALIE) autoantibodies. These results further support the notion that Fc-FcyR 340 341 interaction attenuates the pathogenicity of anti-Dsg1 autoantibodies, and that this process is independent of T cells. Consistently, the PF1-8-15(GASDALIE) autoantibody also induced more 342 343 severe skin lesions and inflammation, as well as increased infiltrating neutrophils in $Fc\gamma R\alpha^{null}$ mice as compared in hFCGR^{Tg} mice (Fig. S7, A to E). 344 FcyR-mediated effector function promotes the clearance of immune complexes and dead 345 *keratinocytes induced by anti-Dsg1 autoantibodies* 346 Since both FcyR-null (N297A) and FcyR-enhanced (GASDALIE) anti-Dsg1 autoantibodies can 347 trigger skin lesions, we reasoned that the observed exacerbation of skin lesions associated with 348 reduced Fc-FcyR binding is due to the impact of FcyR-mediated effector function at the tissue 349 repair stage (Gaipl et al., 2006; Nagata, 2018). Analysis of the levels of remaining anti-Dsg1 350 autoantibodies in the serum of both hFCGR^{Tg} and nude mice showed that in the presence of 351 FcyRs, GASDALIE anti-Dsg1 autoantibodies are depleted faster than N297A anti-Dsg1 352 autoantibodies, suggesting more FcyR-dependent uptake of Dsg1-autoantibodies immune 353 354 complexes (Fig. 6, A and B, and Fig. S6H). Consistently, the levels of Dsg1-autoantigenautoantibody immune complexes were higher in PF1-8-15(N297A)-treated mice than in PF1-8-355

- 356 15(GASDALIE)-treated mice (Fig. 6C). Notably, we also observed more dead keratinocytes at
- skin lesions in PF1-8-15(N297A)-treated nude mice (Fig. 6D), suggesting that FcγR-mediated



358 effector function promotes the clearance of dead keratinocytes.



369

370 *FcyR-enhanced non-pathogenic anti-Dsg1 autoantibodies attenuate skin lesions induced by*

371 *pathogenic anti-Dsg1 antibodies*

372	We further hypothesized that non-pathogenic anti-Dsg1 antibodies could also promote the FcγR-
373	mediated clearance of autoantigen-autoantibody immune complexes and, therefore, the healing
374	of skin lesions. To test this hypothesis, a non-pathogenic but cross-reactive anti-Dsg1
375	autoantibody clone (PF1-2-22) previously isolated from PF patients (Yamagami et al., 2009),
376	was produced as the GASDALIE variant and confirmed to have different binding epitope as
377	pathogenic anti-Dsg1 clones PF1-8-15 and PF24-9 (Fig. S3C, Table S4). Notably, the non-
378	pathogenic PF1-2-22(GASDALIE) could attenuate the skin lesions induced by pathogenic PF1-
379	8-15(N297A) autoantibodies in nude mice, as shown by the reduced skin lesions (Fig. 7, A and
380	B) and epidermal blistering (Fig. 7C). Furthermore, fewer apoptotic keratinocytes in the
381	epidermis were observed in skin tissues isolated from non-pathogenic anti-Dsg1 autoantibody-
382	treated mice (Fig. 7D). These results suggest that the FcyR-mediated effector function can
383	attenuate pathogenic anti-Dsg1 autoantibody-induced skin lesions by promoting the clearance of
384	apoptotic keratinocytes that may otherwise undergo secondary necrosis and induce
385	inflammation, and therefore contribute to the healing of Dsg1 autoantibody-induced skin lesions
386	in pemphigus foliaceus models.





- 393 staining results of skin tissues (C), TUNEL staining results of skin (D) in nude mice 2 days after
- being treated with 0.5 (B) or 0.4 mg (C, D) of pathogenic PF1-8-15(N297A) together with (+) or
- without (-) an equal amount of non-pathogenic (PF1-2-22(GASDALIE)) antibodies, with
- TUNEL positive cells (green) correspond to the epidermis in (H). Scale bars: 200 μm (C) or 100
- μ m (D). Each photo is derived from an individual mouse.

398

399 Discussion

400 It is striking that the IgG4 subclass and Fc-FcyR interaction have the opposite impact on the 401 pathogenicity of autoantibodies isolated from different IgG4-mediated autoimmune diseases. Although the IgG4 autoantibodies are pathogenic in both the TTP and PF patients and animal 402 models, the IgG4 subclass can attenuate the pathogenic function of anti-ADAMTS13 403 autoantibodies when the otherwise more pathogenic IgG1 subclass is considered. This is due, at 404 405 least in part, to its weak FcyR-mediated effector function since either reducing FcyR binding 406 affinity or ablating FcyRs can also attenuate the pathogenicity of anti-ADAMTS13 autoantibodies. In contrast, the IgG4 subclass and Fc-FcyR interaction have the opposite impact 407 408 on the pathogenic function of anti-Dsg1 autoantibodies, since either reducing FcyR binding affinity or ablating FcyRs can exacerbate their pathogenic function. Our results provide direct 409 410 evidence for the differential impact of IgG subclasses on the pathogenic function of autoantibodies. 411

412 Previously, mixed results have been reported regarding the pathogenic potential of IgG1 and 413 IgG4 autoantibodies in both TTP and PF. On the one hand, IgG4 autoantibody-dominant TTP 414 serum samples were recently reported to have a stronger inhibitory effect on ADAMTS13 415 activity than IgG1 autoantibody-dominant TTP serum samples (Sinkovits et al., 2018), despite that this difference does not seem to correlate with disease course in the same study (Sinkovits et 416 al., 2018). On the other hand, patients with high levels of IgG1 and low levels of IgG4 anti-417 418 ADAMTS13 autoantibodies were reported to have high mortality rate (Ferrari et al., 2009); and IgG1 and IgG3, not IgG4 anti-ADAMTS13 autoantibody titers were among the most strongly 419 associated factors with clinical severity of acute TTP (Bettoni et al., 2012). Furthermore, a 420 subclass switching from IgG1 to IgG4, but not IgG4 to IgG1 in anti-ADAMTS13 autoantibodies 421

422	was observed at the first episode/remission transition in TTP (Sinkovits et al., 2018). While these
423	studies established a correlation between IgG subclass and disease severity, a direct comparison
424	between IgG4 and IgG1 autoantibodies has not been allowed given the complexity of polyclonal
425	anti-ADAMTS13 autoantibodies in serological studies. The majority of these studies supported
426	our conclusion that IgG4 is less pathogenic as compared to matched IgG1 anti-ADAMTS13
427	autoantibodies. Also, consistently, the inverse correlation between IgG4 and IgG1 anti-
428	ADAMTS13 autoantibodies and their association with different levels of ADAMTS13 antigen
429	levels have been described previously in an independent study (Ferrari et al., 2009).
430	Regarding the impact of IgG subclass on autoantibody pathogenicity in PF, it has been clear that
431	the emergence of IgG4 anti-Dsg1 autoantibodies has a stronger correlation than IgG1
432	autoantibodies with endemic PF disease activity (Warren et al., 2003). Previously, Fab fragments
433	of anti-Dsg1 antibodies were reported to be more pathogenic as compared to intact IgG4
434	autoantibodies (Rock et al., 1990). While it suggests that the IgG Fc is not essential for anti-Dsg1
435	autoantibody pathogenicity, it also supports a role of IgG4 Fc in modulating the pathogenicity of
436	anti-Dsg1 autoantibodies. Interestingly, "non-pathogenic IgG1 anti-Dsg1 antibodies" described
437	in endemic PF patients in the preclinical stage and healthy controls living in the endemic areas
438	were proposed to have non-pathogenic binding epitopes (Aoki et al., 2015; Li et al., 2003) and
439	no functional roles, as far as we know, have been proposed for the IgG1 subclass and these "non-
440	pathogenic antibodies". Our study provides direct evidence supporting a role of the IgG subclass
441	and Fc-FcyR interaction in the pathogenic function of anti-Dsg1 autoantibodies isolated from PF
442	patients, as well as a potentially protective role of non-pathogenic IgG1 anti-Dsg1 antibodies
443	described previously.

The opposite impact of the IgG4 subclass and Fc-FcyR interaction on the pathogenic function of 444 autoantibodies in anti-ADAMTS13 and anti-Dsg1 autoantibodies suggests that these 445 autoantibodies have different modes of action in IgG4-mediated autoimmune diseases. 446 Previously, many antibodies have been studied for their mode of action and the impact of Fc-447 FcyR engagement. Interestingly, different types of antibodies categorized by mode of action are 448 449 impacted very differently by Fc-FcyR engagement. It has been well-established that effector antibodies, which eliminate their targets (bacteria, virus, toxin, cancer cells et al.), all require 450 451 activating FcyRs to mediated their optimal activities (reviewed in (Bournazos & Ravetch, 2017)). 452 Agonistic antibodies targeting a number of TNF receptor superfamily members (CD40, DR5, CD137, et al.) have been shown to depend on inhibitory FcyRIIB for their optimal activities 453 (reviewed in (Beers, Glennie, & White, 2016)). In contrast, anti-PD1 antibodies that function by 454 455 blocking PD1/PD-L1 interaction have been shown to function best when they do not bind to 456 FcyRs (Dahan et al., 2015). While these findings are important for the design and engineering or 457 antibody applications according to their modes of action, it has not been well-studied whether they apply to autoantibodies, with many of which have unclear modes of action. 458 Our study of anti-ADAMTS13 autoantibodies suggests that they have multiple functional 459 460 mechanisms. On the one hand, their enzyme inhibition ability in the absence of $Fc\gamma Rs$ suggests 461 that anti-ADAMTS13 antibodies can function by blocking, which is consistent with their 462 requirement of specific binding epitopes — autoantibodies targeting the spacer domain and 463 metalloprotease domain of ADAMTS13, which are required for binding to and cleaving its 464 substrate vWF, have been reported to be pathogenic (Feys et al., 2010; Ostertag, Bdeir, et al., 465 2016; Ostertag, Kacir, et al., 2016; Zheng, 2015). On the other hand, the protective effect of the IgG4 subclass (versus IgG1) and FcyR-deficiency in our TTP model suggest that anti-466

ADAMTS13 autoantibodies also function at least in part as effector antibody. Since 467 ADAMTS13 proteins are circulating in the blood, a plausible mechanism would be FcyR-468 mediated depletion of ADAMTS13 can further exacerbate the reduction of ADAMTS13 469 enzymatic activities. This notion is supported by the observation that IgG4-ADAMTS13 immune 470 complexes persist longer than IgG1-ADAMTS13 immune complexes, likely due to reduced 471 472 clearance (Ferrari et al., 2014). In this regard, it is noted that among all the natural human IgG subclasses, IgG4 has the least effector function, suggesting that switching to the IgG4 subclass is 473 a protective mechanism in the context of TTP. 474

The increased pathogenic function of anti-Dsg1 autoantibodies observed in FcyR-deficient mice 475 476 (vs. FcyR-sufficient mice) and in the form of IgG variants with weak binding affinity to FcyRs (vs. IgG variants with enhanced binding affinity to FcyRs) suggest that anti-Dsg1 autoantibodies 477 478 also primarily function as blocking antibodies (Koneczny, 2018). This is also supported by the 479 previous finding that these antibodies require specific binding epitope, and they can function in 480 the form of scFv (Ishii et al., 2008; Yamagami et al., 2009; Yoshida et al., 2017). However, it is intriguing that Fc-FcyR interaction attenuates anti-Dsg1 autoantibody-induced pathogenicity, 481 which suggests that either FcyR-dependent effector function or agonistic function has a 482 483 contribution to the overall effect of anti-Dsg1 autoantibodies. The agonistic function is not likely 484 given that Dsg1-signaling has been suggested to be a pathogenic mechanism (Hammers & 485 Stanley, 2020; Spindler et al., 2018). Since anti-Dsg1 autoantibody-induced skin lesions belong 486 to the type II hypersensitivity, in which the keratinocytes are attacked and inefficiently clearance 487 of apoptotic cells may trigger secondary necrosis and delay the healing, our results support that 488 FcyR-mediated effector function is beneficial for tissue repair and wound healing by contributing 489 to the clearance of Dsg1-autoantibody immune complexes. It will be interesting to investigate

whether other autoantibodies are also involved in the clearance of autoantigen and cell debriscontaining autoantigens.

492	While our study of anti-ADAMTS13 autoantibodies supports the notion that switching to
493	immune-inert IgG4 subclass is a protective mechanism in IgG4-mediated autoimmune diseases,
494	our analysis of anti-Dsg1 autoantibodies suggests the opposite. It appears that the distinct impact
495	of IgG subclass and Fc-FcyR engagement on different antibodies with blocking function lies in
496	the effect of their effector functions in their respective context. In the previously described
497	blocking anti-PD1 antibodies (Dahan et al., 2015), either FcyR-dependent depletion of PD1-
498	expressing T cells or agonistic function of anti-PD1 antibodies results in the reduction of T cell
499	immunity, which counters the effect of blocking PD1 signal in T cells. In the case of anti-
500	ADAMTS13 autoantibodies, FcyR-mediated depletion of ADAMTS13 synergizes with the
501	blocking function of anti-ADAMTS13 autoantibodies to further reduce the enzymatic activity of
502	ADAMTS13. In the case of anti-Dsg1 autoantibodies, the FcγR-mediated effector function may
503	indirectly counter the pathogenic function of anti-Dsg1 autoantibodies by promoting the
504	clearance of apoptotic cells containing autoantigens and tissue repair. Therefore, carefully
505	examining the impact of IgG subclasses and Fc-FcyR interactions on autoantibody functions is
506	critical for understanding their mode of action in the context of different biological processes and
507	disease settings.

508

We analyzed plasma samples of 44 acquired TTP patients investigated in Jiangsu Institute of

509 Materials and Methods

511

510 Patients and samples collection

512 Hematology, The First Affiliated Hospital of Soochow University, Jiangsu, China, between September 2019 and April 2020. This institute is providing diagnostic services for patients in 513 China suspected of having thrombotic microangiopathies. The diagnosis of acquired TTP was 514 515 based on the following criteria: (1) thrombocytopenia (platelet count below 150 G/L) and 516 hemolytic anemia (Coombs-negative anemia, elevated LDH); (2) deficient ADAMTS13 activity 517 (< 5%, measured by R-CBA assay (the residual collagen-binding activity), as described below); and (3) detectable inhibitory anti-ADAMTS13 autoantibodies as analyzed by the R-CBA method 518 (Gerritsen, Turecek, Schwarz, Lammle, & Furlan, 1999). Blood samples were collected during 519 520 an acute episode and anticoagulated with sodium citrate before plasma exchange therapy. Plasma 521 samples were separated by centrifugation and stored at -70°C until measurements. Sodium 522 citrate-anticoagulated plasma samples were used for the determinations of ADAMTS13 activity, 523 ADAMTS13 Ag levels and autoantibody subclasses and concentrations. To study the impact of IgG subclass on the pathogenicity of anti-Dsg1 autoantibodies, 53 PF 524 patients, including 21 patients at stable stage (defined as no new skin lesions and erosions for at 525 526 least 1 month, and with gradually reducing corticosteroid dosage) and 32 patients at active stage (including newly diagnosed patients without any treatment or stable patients developing new 527 528 lesions, lasting more than one week), from Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, China, were recruited and analyzed. All PF 529 patients exclusively had anti-Dsg1 autoantibodies, but not anti-Dsg3 autoantibodies, as detected 530

by ELISA. Serum and sodium citrate-anticoagulated plasma of healthy people was obtained fromthe medical center or healthy blood donors.

533 Mice

534	Adult and neonatal C57BL/6 WT mice and Balb/c nude mice were obtained from SLAC
535	(Shanghai, China). Fc γ R-deficient mouse (Fc γ R α^{null}) (Smith et al., 2012), Fc γ R-humanized
536	$mouse (Fc\gamma R\alpha^{-/-}/hFc\gamma RII^{+}/hFc\gamma RIIA^{R131+}/hFc\gamma RIIB^{+}/hFc\gamma RIIIA^{F158+}/hFc\gamma RIIIB^{+}, shorted for$
537	"hFCGR ^{Tg} ") (Smith et al., 2012), and Fc receptor common γ -chain deficient mouse (<i>Fcer1g</i> ^{-/-})
538	(Clynes, Takechi, Moroi, Houghton, & Ravetch, 1998; Takai, Li, Sylvestre, Clynes, & Ravetch,
539	1994) have been described elsewhere and were kindly provided by Dr. Jeffrey Ravetch (The
540	Rockefeller University). hFCGR ^{Tg} or Fc γ R α^{null} mice produced by breeding or by bone marrow
541	reconstitution were used. The method to generate bone marrow chimeric mice has been
542	described previously (Liu et al., 2019). Briefly, 8-10 weeks female C57BL/6 WT mice (SLAC,
543	Shanghai, China) were lethally irradiated with 8 Gy X-ray using RS 2000pro X-ray biological
544	Irradiator (Rad Source Technologies, Inc., U.S.A.), and 2 x 10^6 bone marrow cells of hFCGR ^{Tg}
545	or $Fc\gamma R\alpha^{null}$ mice were transferred to these irradiated mice through tail vein injection. Successful
546	bone marrow reconstitution was confirmed two months later by analyzing FcyRIIB expression in
547	B cells and CD11b ⁺ myeloid cells in peripheral blood by flow cytometry. Mice were used at the
548	age of 8-12 w or 2-4 months after bone marrow reconstruction used unless stated otherwise.

549 Antibodies

550 The amino acid sequences of the variable region of TTP1-420 anti-ADAMTS13 autoantibody

551 were obtained from a published paper (Ostertag, Kacir, et al., 2016). Nucleic acid sequences of

- the variable region of pathogenic PF1-8-15 and PF24-9 anti-Dsg1 scFv and non-pathogenic PF1-
- 553 2-22 anti-Dsg1 scFv were obtained from the patent (Patent No.: US8846867B2). Antibody heavy

554	chain variable sequences and light chain sequences were synthesized and inserted into the
555	pFL_DEC expression vector with or without human IgG constant region (IgG1 or IgG4),
556	respectively, as described previously (Liu et al., 2019). IgG1 Fc variants with specific mutations
557	(N297A or G236A/S239D/A330L/I332E) were generated by site-directed mutagenesis. Paired
558	antibody heavy and light chain expression vectors were used to transiently co-transfect HEK293
559	cells. IgG antibodies in the supernatant were collected several days later and purified with
560	protein G Sepharose (GE Healthcare), and dialyzed to PBS and stored at 4°C. LPS (endotoxin)
561	levels were analyzed by the Limulus amebocyte lysate assay (Thermo Scientific) and confirmed
562	to be $< 0.01 \text{ EU}/\mu g$.

563 Production of hDsg1 and hDsg2 extracellular domains and their chimeric proteins

564 DNA fragments encoding the signal peptide, pro-sequence and entire extracellular domains of

565 Dsg1 (GenBank accession no. NM_001942) and Dsg2 (GenBank accession no. NM_001943)

566 were obtained by reverse transcription-polymerase chain reaction (RT-PCR, Thermo)

567 amplification using RNA extracted from healthy human skin (obtained from plastic surgery) by

568 TRIzol reagent (Invitrogen) as the template. DNA fragments encoding of Dsg1/Dsg2 chimeric

569 proteins consisting of various extracellular domain segments of Dsg1 were obtained by

570 overlapping PCR using Dsg1 and Dsg2 vectors as the templates. The forward and reverse

primers used are listed in Table S5. BamH1 and Sal1 are added to 5' and 3' end primers,

respectively, and were used for subcloning the DNA fragments encoding of Dsg1/Dsg2 chimeric

573 proteins into the pFastBac1 vector that was engineered to contain the FlagHis tag

574 (dykdddkfvehhhhhhh) sequence between the Sal1 and Not1 sites. The recombinant donor

plasmid was used to transform competent DH10BacTM *E. coli* cells, after which blue-white

576 plaque assay was performed to confirm successful site-specific transposition. Dsg1, Dsg2, and

577 Dsg1/Dsg2 chimeric proteins were expressed in the Sf9 cells and purified as previously

578 described (Ding, Diaz, Fairley, Giudice, & Liu, 1999).

579 ELISA

To measure the binding ability of human IgG and Fc variants to mouse FcyRs, a previously 580 described protocol (Liu et al., 2019) was modified. Briefly, 100 µl of 2 µg/ml TTP1-420 anti-581 ADAMTS13 antibodies with various constant domains (IgG1/IgG4/N297A/GASDALIE) were 582 coated in 96-well MaxiSorp[™] flat plate (Nunc) at 4°C overnight. After discarding the liquid and 583 584 washing with PBS containing 0.05% Tween-20 (PBST), the plates were blocked with 200 µl of 1 585 or 2% BSA at room temperature for 2 h and washed 2 times with PBST, after which 100 µl of 586 serially diluted (0.001-1 µg/ml, 1:3.16) biotinylated mouse FcyRs (Sino Biological) were added 587 and incubated at RT for 1 h. Plates were then washed 3 times with PBST and further incubated with 100 µl of diluted Streptavidin-HRP (1:1000, BD PharmingenTM) for 1 h, and followed by 588 589 washing four times and developing with 100 µl of TMB peroxidase substrate (KPL). The 590 absorbance at 650 nm was recorded using a multifunctional microplate reader (SpectraMax[®]i3, Molecular Devices). 591

592 Similar protocols were applied to other ELISA analyses with except that when Dsg1, Dsg2, or

593 Dsg1/2 chimeric proteins were involved, all reagents were dissolved or diluted in TBS-Ca buffer

- 594 (TBS buffer with 1 mM CaCl₂) and TBS-Ca-T (TBS-Ca containing 0.05% Tween-20) was used
- so as washing buffer, as well as the following:
- 1) To detect the binding kinetics of TTP1-420 anti-ADAMTS13 or PF1-8-15 anti-Dsg1
- 597 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) to their antigens,
- respectively, ADAMTS13 (R&D Systems, diluted with bicarbonate/carbonate buffer containing
- 599 15 mM Na₂CO₃ and 35 mM NaHCO₃, pH = 9.6) and recombined Dsg1 was coated. Serially

- 600 diluted specific and Ctrl hIgG (Jackson ImmunoResearch Laboratories) (0.00316-3.16 μg/ml)
- 601 were analyzed; TTP1-420(IgG1) was used as irrelevant IgG1 control for anti-Dsg1 antibodies.
- Biotinylated mouse anti-human lambda chain (1:2000, Clone JDC-12 (RUO), BD
- 603 Pharmingen[™]) was used as detecting antibody.
- 2) To compare the binding epitopes of different anti-Dsg1 antibody clones, different anti-Dsg1

IgG1 antibody clones (PF1-8-15, PF24-9, or PF1-2-22) or TBS-Ca as negative control were

606 coated; recombined Dsg1 (1 μ g/ml) was analyzed; biotinylated PF1-8-15(IgG1) (1 μ g/ml), or

 α CD40(IgG1) (1 µg/ml, as negative control) (EZ-Link[®] Micro Sulfo-NHS-Biotinylation Kit

- 608 (Thermo scientific)) was used as detecting antibody.
- 3) To determine the total IgG, IgG1, and IgG4 anti-ADAMTS13 antibodies in TTP and HC

plasma samples, ADAMTS13 was coated; sodium citrate-anticoagulated plasma (dilution: 1 to

611 100 for IgG, 1 to 10 for IgG1 and IgG4) were analyzed; serially-diluted TTP1-420(IgG1) and

612 TTP1-420(IgG4) antibodies were used as standards of IgG1 and IgG4, respectively; HRP-

613 conjugated goat anti-human IgG Fc (1:10000, Bethyl Laboratories), mouse anti-human IgG1

614 (1:3160, 4E3, Southern Biotech) and IgG4 (1:3160, HP6025, Southern Biotech) were used as

detecting antibodies. IgG1 and IgG4 anti-ADAMTS13 antibody levels were calculated based on

their respective standard curves and normalized to HC controls ((TTP anti-ADAMTS13

617 levels)/(HC anti-ADAMTS13 average levels)) (considering the background caused by non-

specific IgG in plasma). Based on the relative normalized IgG1 and IgG4 anti-ADAMTS13

antibody levels, TTP patients were divided into "IgG1-dominant TTP" and "IgG4-dominant

620 TTP" groups.

4) To determine the total IgG, IgG1, and IgG4 anti-Dsg1 antibodies in PF and HC serum

samples, recombined Dsg1 was coated, and diluted serum samples (dilution: 1 to 100 for IgG1, 1

623	to 1000 for IgG4 and IgG) were analyzed, together with serially diluted PF24-9(IgG1) and PF24-
624	9(IgG4) antibodies as references (0.316 μ g/ml as positive controls (PC)); HRP-conjugated goat
625	anti-human IgG Fc (1:10000, Bethyl Laboratories), mouse anti-human IgG1 (1:2000, HP6070,
626	Thermo) and IgG4 (1:2000, HP6023, Thermo) were used as detecting antibodies; unit values of
627	Dsg1-specific IgG, IgG1 and IgG4 antibodies were calculated according to the commercial anti-
628	Dsg1 IgG detecting kit (Medical & Biological Laboratories) using the following formula:
629	$(OD650_{sample}-OD650_{HC})/(OD650_{PC}-OD650_{HC})*Dilution factor.$
630	5) To analyze the binding epitopes of anti-Dsg1 IgG1 and IgG4 antibodies in PF serum,
631	recombined human Dsg1, Dsg2 and Dsg1/2 chimeric proteins (5 μ g/ml) were coated and 1:100
632	diluted serum samples were analyzed; HRP-conjugated mouse anti-human IgG1 (1:2000,
633	HP6070, Thermo) and IgG4 (1:2000, HP6023, Thermo) were used as detecting antibodies.
634	6) To detect the levels of free hIgG in mouse serum samples, goat anti-human IgG (H+L)
635	(Jackson ImmunoResearch Laboratories) was coated and serum samples diluted to optimized
636	concentration were analyzed (1:100 or 1:1000); goat anti-human IgG (H+L) HRP (1:10000,
637	Bethyl Laboratories) or biotinylated mouse anti-human lambda chain (1:2000, JDC-12 (RUO),
638	BD Pharmingen TM) combined with Streptavidin-HRP (1:1000, BD Pharmingen TM) were used as
639	detecting antibodies for Ctrl hIgG and anti-Dsg1 IgG1 variants.
640	7) To detect the levels of Dsg1-specific immune complexes (IC), non-pathogenic PF1-2-
641	22(IgG4) (5 μ g/ml) was coated at 37°C for 6 h; diluted serum samples (1:100) were analyzed;
642	mouse anti-hIgG1 HRP (1:3160, 4E3, Southern Biotech) was used as detecting antibody.

643 ADAMTS13 activity assays (FRETS-VWF73)

644	To analyze mouse ADAMTS13 activity, a published protocol (Kokame, Nobe, Kokubo,
645	Okayama, & Miyata, 2005; Ostertag, Kacir, et al., 2016) was used with modification. Briefly, 4.8
646	μl of plasma sample was diluted with 25.2 μl assay buffer (5 mM Bis-Tris, 25 mM CaCl_2,
647	0.005% Tween 20, pH = 6). Ten μ l of the diluted sample was then transferred to a 384-well
648	white plate (Cisbio), and mixed with 10 μ l of diluted FRETS-VW73 substrate (4 μ M, Anaspec).
649	Related fluorescence units (RFU) of cleaved FRETS-VWF73 were measured for 1 h using a
650	multi-mode microplate reader (Synergy H1, BioTek) with the following setting: excitation at 340
651	nm and emission at 450 nm. Related fluorescence units (RFU) were recorded for 1 h, and their
652	changing rates over time were calculated and expressed as "RFU/min".

653 ADAMTS13 activity assay (R-CBA)

654 ADAMTS13 activity of human plasma was assayed by evaluating collagen-binding activity

655 (CBA) as previously described with modifications (Yue et al., 2018). In brief, 50 µl of sodium

656 citrate-anticoagulated plasma samples from patients and healthy controls were placed in Slide-A-

657 Lyzer mini dialysis units (Pierce) and immersed in dialysis buffer (5 mM Tris-HCl, 0.1% Tween

658 20, and 1.5 M urea, pH = 8.3). Dialysis was performed at 37°C for 3 h. An equal volume of the

659 same sample was removed before dialysis and kept at room temperature during the dialysis as a

660 control. The collagen type III binding capacities of the samples were then detected by ELISA.

The data were analyzed as the fraction of CBA remaining after dialysis compared with the CBA 661

of the individuals' baseline samples. One hundred percent minus the residual CBA was regarded 662

- 663 as the ADAMTS13 activity.
- 664 **ADAMTS13** antigen quantification

665 ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer's instructions 666

- with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were
- used; (2) the range of the standard curve was broadened to 0.78125-100 ng/ml.
- 669 The activity of anti-ADAMTS13 antibodies in mice
- 670 WT C57BL/6, hFCGR^{Tg}, Fc γ R α^{null} , or *Fcer1g*^{-/-} mice were treated with 10 µg per mouse of
- 671 TTP1-420 anti-ADAMTS13 antibodies with different constant domains
- 672 (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on
- 673 day 0 through tail vein injection. Blood samples were drawn at the time points described in the
- results and anticoagulated with 4% sodium citrate. Plasma was obtained after centrifugation and
- stored at -20°C for several days before analyzing. ADAMTS13 activity was analyzed using the
- 676 VWF73-FRET method described above.

677 Mouse model of pemphigus foliaceus

- 678 WT C57BL/6 neonatal mice born within 48 hours (SLAC, Shanghai, China) were
- subcutaneously injected with the same amount of control hIgG (Jackson ImmunoResearch

Laboratories), IgG1 or IgG4 anti-Dsg1 autoantibodies in 50 μl (15.8 μg/mouse for PF24-9 and

681 10 μg/mouse for PF1-8-15) and euthanized 7 hours later to collect skin samples for hematoxylin-

682 eosin (HE) staining.

Adult hFCGR^{Tg} and Fc γ R α^{null} mice were treated with pathogenic anti-Dsg1 antibodies and control hIgG through tail vein injection at the dosage described in the results on day 0. Skin or ear thickness was measured by caliper; orbital blood was collected to prepare serum. After mice were euthanized, one ear was digested for flow cytometry analysis, and the other was subjected to hematoxylin-eosin (HE) staining.

688	To compare the pathogenicity of PF1-8-15(N297A) and PF1-8-15(GASDALIE) anti-Dsg1
689	antibodies, 8-10 w old female nude mice (SLAC, Shanghai, China) were treated with 0.4-0.5
690	mg/mouse antibodies (as specified in Figure legends) via tail vein injection on day 0. On day 2
691	and 4, photographs were taken to record skin lesions, and blood was drawn to prepare serum.
692	The levels of free anti-Dsg1 antibodies and Dsg1-specific ICs were analyzed in serum samples.
693	To study the impact of non-pathogenic anti-Dsg1 antibodies (PF1-2-22) optimized for Fc-FcγR
694	interaction, pathogenic PF1-8-15(N297A) anti-Dsg1 antibodies (0.4-0.5 mg/mouse, as specified
695	in Figure legends) were injected to 7-9 w male nude mice (SLAC, Shanghai, China) with or
696	without an equal amount of non-pathogenic PF1-2-22(GASDALIE) antibodies. Cutaneous
697	lesions were recorded on day 2, and skin samples were harvested for histopathology examination
698	and TUNEL assay after mice were sacrificed.

699 Flow cytometry analysis

Mouse ears were cut and split into dorsal/ventral surfaces with forceps and digested with 2 ml of 700 701 dispase II solution (2.5 mg/ml in PBS with 2% FBS, Roche) in 6-well plate at 37 °C for 90 min 702 with shaking. After separating dermis from the epidermis using forceps, tissues (both epidermis 703 and dermis) were cut into tiny pieces and put into RPMI 1640 complete medium (RPMI 1640, 704 10% FBS, 1% Pen/Strep) containing 0.5 mg/ml of collagenase IV (Sigma/biosharp) and 100 705 U/ml of DNase I (Sigma) for incubating at 37°C for 60 min to complete the digestion. The 706 digested tissue was then passed through a 70 µm cell strainer, and the debris was ground and 707 washed through the cell strainer using 35 ml of cold PBS. Cells were collected and resuspended with 600 µl FACS buffer (PBS buffer with 0.5% FBS and 2 mM EDTA). Half of the 708 709 resuspended ear cells were stained with 1 µg/ml of Alexa Fluor 700 conjugated mouse anti-710 mouse CD45.2 (104, BD), APC conjugated rat anti-mouse CD11b (M1/70, eBioscience) and

711	FITC conjugated rat anti-mouse Gr1 (RB6-8C5, eBioscience). DAPI (0.5 µg/ml, Invitrogen) and
712	CountBright TM Absolute Counting Bead (3 µl/sample, Life technologies) were added to
713	resuspend cells before analyzing using a BD LSRFortessa [™] X-20 analyzer (BD Biosciences).
714	Data were analyzed using FlowJo X. Gating strategy was shown in Fig. S8.
715	TUNEL assay
716	TUNEL staining was conducted per manufacturer instructions (Roche). Images were obtained
717	via OLYMPUS BX51 Confocal Microscope outfitted with a 10x or 40x objective. Apoptotic
718	cells were defined as cells possessing a TUNEL positive (green) pyknotic nucleus.
719	Statistics
720	Statistical analyses were performed with Prism GraphPad 6.0, and p values less than 0.05 were
721	considered to be statistically significant. Asterisks indicate statistical difference within two
722	interested groups on the figures (* p < 0.05. ** p < 0.01, *** p < 0.001, **** p < 0.0001).
723	Study approval
724	Ethical approval was obtained from the Ethics Committees in The Rui Jin Hospital of Shanghai
725	Jiao Tong University School of Medicine and The First Affiliated Hospital of Soochow
726	University, respectively. All PF and TTP patients and healthy volunteers signed informed
727	consent. All mice were bred and maintained under specific pathogen-free (SPF) conditions, and
728	all animal experiments were performed under the institutional guidelines of the Shanghai Jiao
729	Tong University School of Medicine Institutional Animal Care and Use Committee.
730	

731 Author contributions

- F.L., Y.M.Z, and Y.B. designed the experiments; J.S., S.Z. and Y.B. collected the human
- samples; Y.B., J.S., Y.Z., Y.J.Z., H.Z., and M.L. performed experiments. A.Z., and J.S. provided
- technical supports; F.L., Y.M.Z, and Y.B. analyzed results, F.L., Y.M.Z, M.P., and Y.B. wrote
- the paper.

736 Acknowledgments

- 737 We thank Dr. Jeffrey Ravetch of The Rockefeller University for providing FcγR-deficient mouse
- 738 (Fc γ R α^{null}), Fc γ R-humanized mouse (hFCGR^{Tg}) and Fc receptor common γ -chain deficient
- mouse (*Fcer1g*^{-/-}), and pFL_DEC expression vector. We acknowledge the assistance of staff in
- the Department of Laboratory Animal Science, Shanghai Jiao Tong University School of
- 741 Medicine and Shanghai Institute of Immunology. Funding: This work was supported by NNSFC
- 742 projects No. 31422020 and 31870924. Y.M.Z. is supported by NNSFC project No. 81873431
- and Jiangsu Provincial Natural Science Foundation No. BK20181164. Y.Z. is supported by
- 744 Shanghai Sailing Program No. 16YF1409700. H.Z. is supported by Shanghai Municipal Natural
- Science Foundation project No. 15ZR1436400 and Shanghai Young Oriental scholar program
- 746 2015 by Shanghai Municipal Education Commission. F.L., Y.Z., and H.Z. are also supported by
- the innovative research team of high-level local universities in Shanghai (SSMU-
- 748 2DCX20180100).
- Competing interests: A patent application based on the study is being prepared for submission,
 and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors.

751

752 **References**

- 753 Akdis, C. A., & Akdis, M. (2011). Mechanisms of allergen-specific immunotherapy. J Allergy
- 754 *Clin Immunol, 127*(1), 18-27; quiz 28-19. doi:10.1016/j.jaci.2010.11.030
- Anhalt, G. J., Labib, R. S., Voorhees, J. J., Beals, T. F., & Diaz, L. A. (1982). Induction of
- pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N
- 757 *Engl J Med*, *306*(20), 1189-1196. doi:10.1056/NEJM198205203062001
- Aoki, V., Rivitti, E. A., Diaz, L. A., & Cooperative Group on Fogo Selvagem, R. (2015). Update
- on fogo selvagem, an endemic form of pemphigus foliaceus. *J Dermatol*, 42(1), 18-26.
- 760 doi:10.1111/1346-8138.12675
- 761 Beers, S. A., Glennie, M. J., & White, A. L. (2016). Influence of immunoglobulin isotype on
- therapeutic antibody function. *Blood*, *127*(9), 1097-1101. doi:10.1182/blood-2015-09625343
- 764 Bettoni, G., Palla, R., Valsecchi, C., Consonni, D., Lotta, L. A., Trisolini, S. M., . . . Peyvandi, F.
- 765 (2012). ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic
- predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost, 10(8),
- 767 1556-1565. doi:10.1111/j.1538-7836.2012.04808.x
- 768 Bournazos, S., DiLillo, D. J., Goff, A. J., Glass, P. J., & Ravetch, J. V. (2019). Differential
- requirements for FcgammaR engagement by protective antibodies against Ebola virus.
- 770 Proc Natl Acad Sci US A, 116(40), 20054-20062. doi:10.1073/pnas.1911842116
- 771 Bournazos, S., & Ravetch, J. V. (2017). Diversification of IgG effector functions. Int Immunol,
- *29*(7), 303-310. doi:10.1093/intimm/dxx025

- 773 Clynes, R., Dumitru, C., & Ravetch, J. V. (1998). Uncoupling of immune complex formation and
- kidney damage in autoimmune glomerulonephritis. *Science*, *279*(5353), 1052-1054.
- doi:10.1126/science.279.5353.1052
- Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998). Fc receptors are
- required in passive and active immunity to melanoma. *Proc Natl Acad Sci U S A*, 95(2),
- 778 652-656. doi:10.1073/pnas.95.2.652
- 779 Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015).
- FcgammaRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1
- 781 Axis. Cancer Cell, 28(3), 285-295. doi:10.1016/j.ccell.2015.08.004
- 782 Devey, M. E., Lee, S. R., Richards, D., & Kemeny, D. M. (1989). Serial studies on the functional
- affinity and heterogeneity of antibodies of different IgG subclasses to phospholipase A2
 produced in response to bee-venom immunotherapy. *J Allergy Clin Immunol*, *84*(3), 326-
- 785 330. doi:10.1016/0091-6749(89)90416-8
- Ding, X., Diaz, L. A., Fairley, J. A., Giudice, G. J., & Liu, Z. (1999). The anti-desmoglein 1
- autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol, 112(5),
- 788 739-743. doi:10.1046/j.1523-1747.1999.00585.x
- 789 Ferrari, S., Mudde, G. C., Rieger, M., Veyradier, A., Kremer Hovinga, J. A., & Scheiflinger, F.
- 790 (2009). IgG subclass distribution of anti-ADAMTS13 antibodies in patients with
- acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost*, 7(10), 1703-1710.
- 792 doi:10.1111/j.1538-7836.2009.03568.x
- 793 Ferrari, S., Palavra, K., Gruber, B., Kremer Hovinga, J. A., Knobl, P., Caron, C., ...
- 794 Scheiflinger, F. (2014). Persistence of circulating ADAMTS13-specific immune

755 COMPLEXES IN DALIENTS WITH ACQUIED UNDOUC UNDOUC VIODENIC DUIDUR	795 con	plexes in	patients with	acquired thro	ombotic thromboo	cytopenic purpura
--	---------	-----------	---------------	---------------	------------------	-------------------

- 796 *Haematologica*, 99(4), 779-787. doi:10.3324/haematol.2013.094151
- Feys, H. B., Roodt, J., Vandeputte, N., Pareyn, I., Lamprecht, S., van Rensburg, W. J., ...
- 798 Vanhoorelbeke, K. (2010). Thrombotic thrombocytopenic purpura directly linked with
- ADAMTS13 inhibition in the baboon (Papio ursinus). *Blood*, *116*(12), 2005-2010.
- 800 doi:10.1182/blood-2010-04-280479
- Furtado, T. A. (1959). Histopathology of pemphigus foliaceus. *AMA Arch Derm, 80*(1), 66-71.
 doi:10.1001/archderm.1959.01560190068010
- Gaipl, U. S., Kuhn, A., Sheriff, A., Munoz, L. E., Franz, S., Voll, R. E., . . . Herrmann, M.
- 804 (2006). Clearance of apoptotic cells in human SLE. *Curr Dir Autoimmun*, *9*, 173-187.
 805 doi:10.1159/000090781
- 806 Gerritsen, H. E., Turecek, P. L., Schwarz, H. P., Lammle, B., & Furlan, M. (1999). Assay of von

807 Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity

808 of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura

809 (TTP). *Thromb Haemost*, 82(5), 1386-1389.

810 Hammers, C. M., & Stanley, J. R. (2020). Recent Advances in Understanding Pemphigus and

Bullous Pemphigoid. *J Invest Dermatol*, *140*(4), 733-741. doi:10.1016/j.jid.2019.11.005

- Huijbers, M. G., Plomp, J. J., van der Maarel, S. M., & Verschuuren, J. J. (2018). IgG4-mediated
- 813 autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci,
- 814 *1413*(1), 92-103. doi:10.1111/nyas.13561
- Ishii, K., Lin, C., Siegel, D. L., & Stanley, J. R. (2008). Isolation of pathogenic monoclonal anti-
- 816 desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.
- 817 *J Invest Dermatol*, *128*(4), 939-948. doi:10.1038/sj.jid.5701132

- Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., ... Mathis, D.
- 819 (2002). Arthritis critically dependent on innate immune system players. *Immunity*, 16(2),
- 820 157-168. doi:10.1016/s1074-7613(02)00275-3
- Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A., & Miyata, T. (2005). FRETS-VWF73, a first
- fluorogenic substrate for ADAMTS13 assay. *Br J Haematol*, *129*(1), 93-100.
- 823 doi:10.1111/j.1365-2141.2005.05420.x
- Koneczny, I. (2018). A New Classification System for IgG4 Autoantibodies. *Front Immunol*, 9,
 97. doi:10.3389/fimmu.2018.00097
- 826 Korman, N. J., Eyre, R. W., Klaus-Kovtun, V., & Stanley, J. R. (1989). Demonstration of an
- adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and
 pemphigus vulgaris. *N Engl J Med*, *321*(10), 631-635.
- doi:10.1056/NEJM198909073211002
- Li, N., Aoki, V., Hans-Filho, G., Rivitti, E. A., & Diaz, L. A. (2003). The role of intramolecular
- epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J
- *Exp Med*, *197*(11), 1501-1510. doi:10.1084/jem.20022031
- Lighaam, L. C., & Rispens, T. (2016). The Immunobiology of Immunoglobulin G4. *Semin Liver Dis*, 36(3), 200-215. doi:10.1055/s-0036-1584322
- 835 Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., . . . Li, F. (2019). Human
- immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and
- antitumour activities through biophysical flexibility. *Nat Commun, 10*(1), 4206.
- doi:10.1038/s41467-019-12097-6

- 839 McGaha, T. L., Sorrentino, B., & Ravetch, J. V. (2005). Restoration of tolerance in lupus by
- targeted inhibitory receptor expression. *Science*, *307*(5709), 590-593.
- doi:10.1126/science.1105160
- Nagata, S. (2018). Apoptosis and Clearance of Apoptotic Cells. *Annu Rev Immunol, 36*, 489-517.
- 843 doi:10.1146/annurev-immunol-042617-053010
- 844 Ostertag, E. M., Bdeir, K., Kacir, S., Thiboutot, M., Gulendran, G., Yunk, L., ... Siegel, D. L.
- 845 (2016). ADAMTS13 autoantibodies cloned from patients with acquired thrombotic
- thrombocytopenic purpura: 2. Pathogenicity in an animal model. *Transfusion*, 56(7),
- 847 1775-1785. doi:10.1111/trf.13583
- 848 Ostertag, E. M., Kacir, S., Thiboutot, M., Gulendran, G., Zheng, X. L., Cines, D. B., & Siegel, D.
- L. (2016). ADAMTS13 autoantibodies cloned from patients with acquired thrombotic
- thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
- 851 *Transfusion*, 56(7), 1763-1774. doi:10.1111/trf.13584
- Rados, J. (2011). Autoimmune blistering diseases: histologic meaning. *Clin Dermatol*, 29(4),
- 853 377-388. doi:10.1016/j.clindermatol.2011.01.007
- 854 Rihet, P., Demeure, C. E., Dessein, A. J., & Bourgois, A. (1992). Strong serum inhibition of
- specific IgE correlated to competing IgG4, revealed by a new methodology in subjects
- from a S. mansoni endemic area. *Eur J Immunol, 22*(8), 2063-2070.
- doi:10.1002/eji.1830220816
- 858 Rock, B., Labib, R. S., & Diaz, L. A. (1990). Monovalent Fab' immunoglobulin fragments from
- endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal
- 860 Balb/c mice. J Clin Invest, 85(1), 296-299. doi:10.1172/JCI114426

- 861 Rock, B., Martins, C. R., Theofilopoulos, A. N., Balderas, R. S., Anhalt, G. J., Labib, R. S., ...
- B62 Diaz, L. A. (1989). The pathogenic effect of IgG4 autoantibodies in endemic pemphigus
- 863 foliaceus (fogo selvagem). *N Engl J Med*, *320*(22), 1463-1469.
- doi:10.1056/NEJM198906013202206
- 865 Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., & Wittrup, K. D. (2008).
- Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.
- 867 Proc Natl Acad Sci U S A, 105(51), 20167-20172. doi:10.1073/pnas.0809257105
- 868 Schmidt, E., Kasperkiewicz, M., & Joly, P. (2019). Pemphigus. *Lancet*, 394(10201), 882-894.
- doi:10.1016/S0140-6736(19)31778-7
- 870 Schumacher, M. J., Egen, N. B., & Tanner, D. (1996). Neutralization of bee venom lethality by

immune serum antibodies. *Am J Trop Med Hyg*, 55(2), 197-201.

- doi:10.4269/ajtmh.1996.55.197
- 873 Shiokawa, M., Kodama, Y., Kuriyama, K., Yoshimura, K., Tomono, T., Morita, T., . . . Chiba, T.
- 874 (2016). Pathogenicity of IgG in patients with IgG4-related disease. *Gut*, 65(8), 1322-
- 875 1332. doi:10.1136/gutjnl-2015-310336
- 876 Sinkovits, G., Szilagyi, A., Farkas, P., Inotai, D., Szilvasi, A., Tordai, A., . . . Prohaszka, Z.
- 877 (2018). Concentration and Subclass Distribution of Anti-ADAMTS13 IgG
- 878 Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic
- Thrombocytopenic Purpura. *Front Immunol*, *9*, 1646. doi:10.3389/fimmu.2018.01646
- 880 Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012). Mouse model
- 881 recapitulating human Fcgamma receptor structural and functional diversity. *Proc Natl*
- 882 *Acad Sci U S A, 109*(16), 6181-6186. doi:10.1073/pnas.1203954109

- 883 Spindler, V., Eming, R., Schmidt, E., Amagai, M., Grando, S., Jonkman, M. F., ... Waschke, J.
- 884 (2018). Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. *J Invest*
- 885 *Dermatol, 138*(1), 32-37. doi:10.1016/j.jid.2017.06.022
- Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994). FcR gamma chain deletion
- results in pleiotrophic effector cell defects. *Cell*, 76(3), 519-529. doi:10.1016/0092-
- 888 8674(94)90115-5
- 889 Umehara, H., Okazaki, K., Nakamura, T., Satoh-Nakamura, T., Nakajima, A., Kawano, M., . . .
- 890 Chiba, T. (2017). Current approach to the diagnosis of IgG4-related disease -
- 891 Combination of comprehensive diagnostic and organ-specific criteria. *Mod Rheumatol*,
- 892 27(3), 381-391. doi:10.1080/14397595.2017.1290911
- van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martinez-Martinez, P.,
- Vermeulen, E., ... Parren, P. W. (2007). Anti-inflammatory activity of human IgG4
- antibodies by dynamic Fab arm exchange. *Science*, *317*(5844), 1554-1557.
- doi:10.1126/science.1144603
- Vidarsson, G., Dekkers, G., & Rispens, T. (2014). IgG subclasses and allotypes: from structure
 to effector functions. *Front Immunol*, *5*, 520. doi:10.3389/fimmu.2014.00520
- 899 Warren, S. J., Arteaga, L. A., Rivitti, E. A., Aoki, V., Hans-Filho, G., Qaqish, B. F., . . . Diaz, L.
- A. (2003). The role of subclass switching in the pathogenesis of endemic pemphigus
 foliaceus. *J Invest Dermatol*, *120*(1), 104-108. doi:10.1046/j.1523-1747.2003.12017.x
- 902 Yamagami, J., Kacir, S., Ishii, K., Payne, A. S., Siegel, D. L., & Stanley, J. R. (2009). Antibodies
- to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned
- from individuals without pemphigus. *J Immunol*, 183(9), 5615-5621.
- 905 doi:10.4049/jimmunol.0901691

906 I OSITIUA, N., ISITI, N., SITITITZU, A., I OKOUCITI, WI., ATTAGAI, WI., SITIFAISITI, N., \ldots I

- 907 (2017). Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly
- pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1
- 909 clustering. *J Dermatol Sci*, 85(3), 197-207. doi:10.1016/j.jdermsci.2016.12.010
- 910 Yuan, H., Zhou, S., Liu, Z., Cong, W., Fei, X., Zeng, W., . . . Pan, M. (2017). Pivotal Role of
- 911 Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. J Invest
- 912 *Dermatol, 137*(11), 2362-2370. doi:10.1016/j.jid.2017.05.032
- 913 Yue, C., Su, J., Gao, R., Wen, Y., Li, C., Chen, G., . . . Li, X. (2018). Characteristics and
- 914 Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic
- 915 Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. *J Rheumatol*,
- 916 *45*(11), 1549-1556. doi:10.3899/jrheum.170811
- 917 Zheng, X. L. (2015). ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic

918 purpura. Annu Rev Med, 66, 211-225. doi:10.1146/annurev-med-061813-013241

- 219 Zhou, S., Liu, Z., Yuan, H., Zhao, X., Zou, Y., Zheng, J., & Pan, M. (2019). Autoreactive B Cell
- 920 Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus
- 921 Lesions. *J Invest Dermatol*. doi:10.1016/j.jid.2019.07.717

922